During the past decade, Kyoto Kuramaguchi Medical Center conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Kyoto Kuramaguchi Medical Center" are "Amyloidosis" (1 trials), "Hematologic Malignancies" (1 trials), "Relapsed and/or Refractory Multiple Myeloma" (1 trials), "Relapsed or Refractory Multiple Myeloma" (1 trials) and "Smoldering Multiple Myeloma" (1 trials). Many other conditions were trialed in "Kyoto Kuramaguchi Medical Center" in a lesser frequency.

Most popular intervention types in "Kyoto Kuramaguchi Medical Center" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (2 trials), "Daratumumab" (2 trials), "Dexamethasone" (2 trials), "Carfilzomib" (1 trials) and "Cyclophosphamide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kyoto Kuramaguchi Medical Center" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Kyoto Kuramaguchi Medical Center". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Kyoto Kuramaguchi Medical Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kyoto Kuramaguchi Medical Center, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".